The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback